Catherine Miller Selected Research

diroximel fumarate

6/2021	Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence.
1/2021	Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study.
11/2020	Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
1/2020	Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
11/2019	Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Catherine Miller Research Topics

Disease

7	Multiple Sclerosis 01/2022 - 01/2019
7	Relapsing-Remitting Multiple Sclerosis 01/2022 - 11/2019
2	Neoplasms (Cancer) 06/2021 - 01/2017
2	Osteonecrosis (Kienbock's Disease) 06/2021 - 09/2020
2	Anorexia Nervosa 04/2021 - 12/2018
2	Infections 11/2008 - 06/2005
1	Atrophy 01/2022
1	Osteoporosis 06/2021
1	Hypoglycemia (Reactive Hypoglycemia) 01/2021
1	Periodontitis 12/2020
1	Avoidant Restrictive Food Intake Disorder 12/2018
1	Feeding and Eating Disorders (Eating Disorder) 12/2018
1	Bradycardia 12/2018
1	Bulimia (Binge Eating) 12/2018
1	Fatigue 12/2018
1	Hypotension (Low Blood Pressure) 12/2018
1	Weight Loss (Weight Reduction) 12/2018
1	Bulimia Nervosa 12/2018
1	Binge-Eating Disorder (Binge Eating Disorder) 12/2018
1	Colitis 01/2018
1	Body Weight (Weight, Body) 01/2018
1	Inflammation (Inflammations) 01/2018
1	Astrocytoma (Pilocytic Astrocytoma) 03/2017
1	Delirium 07/2014
1	Jaundice (Icterus) 06/2014
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2009

Drug/Important Bio-Agent (IBA)

8	Dimethyl FumarateIBA 01/2022 - 01/2019
5	diroximel fumarateIBA 06/2021 - 11/2019
4	FumaratesIBA 01/2021 - 11/2019
2	Diphosphonates (Bisphosphonates)IBA 06/2021 - 09/2020
1	Fingolimod Hydrochloride (FTY720)FDA Link 01/2022
1	Dental Implants (Dental Implant)IBA 06/2021
1	Denosumab FDA Link 06/2021
1	TitaniumIBA 09/2020
1	Alendronate (Alendronate Sodium)FDA LinkGeneric 09/2020
1	Zoledronic Acid (Zometa)FDA Link 09/2020
1	ElectrolytesIBA 12/2018
1	InflammasomesIBA 01/2018
1	CytokinesIBA 01/2018
1	trametinibIBA 03/2017
1	MitogensIBA 03/2017
1	Protein Kinases (Protein Kinase)IBA 03/2017
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	BilirubinIBA 06/2014
1	Alanine Transaminase (SGPT)IBA 06/2014
1	VaccinesIBA 11/2008
1	Immunoglobulin G (IgG)IBA 06/2005

Therapy/Procedure

3	Therapeutics 06/2021 - 03/2017
1	Secondary Prevention 04/2021
1	Length of Stay 01/2021
1	Diet Therapy (Therapy, Diet) 12/2018
1	Drug Therapy (Chemotherapy) 03/2017
1	Occupational Therapy (Therapy, Occupational) 07/2014
1	Chemoradiotherapy 09/2009